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Abstract
The mammary epithelium contains multipotent stem cells that give
rise to all differentiated cell types present within the tissue.
Mammary epithelial stem cells have been prospectively purified
from dissociated mammary epithelium on the basis of cell surface
antigen expression. It has become apparent in recent years that for
breast cancer and other malignancies only a small proportion of
tumour cells — ‘cancer stem cells’ — have the capacity for extensive
proliferation and transferral of the tumour. We review the evidence
for breast cancer stem cells, we consider their relationship to
mammary epithelial stem cells and we examine the implications for
current and future therapeutic strategies.
Introduction
Proliferation in most continuously renewing tissues is
hierarchically organised, with a small number of infrequently
dividing pluripotent stem cells and a larger number of rapidly
dividing ‘transit amplifying’ cells with more limited develop-
mental potential [1]. This is best characterised for the murine
haematopoietic system, where a single cell with the Lin–,
c-Kit+, Sca-1+ phenotype is capable of long-term reconsti-
tution of a lethally irradiated recipient [2]. There is evidence
for a similar organisation in other renewing tissues, such as
the intestinal epithelium [3] and the epidermis [4]. Analogous
techniques have more recently been employed in the
identification of mammary epithelial stem cells.
Following reports that proliferation in certain leukaemias is
organised in a hierarchical manner reminiscent of stem cell
compartments [5], the concept has emerged that only a
minority of ‘cancer stem cells’ have the capacity for self-
renewal and transferral of the tumour [6]. A similar subset of
tumour cells has been isolated from breast malignancies [7]
and neural malignancies [8]. In the present article we review
the evidence for stem cells in the normal mammary
epithelium, we evaluate the recent reports of stem cells in
breast cancer and we assess the implications for current and
future therapeutic strategies.
Stem cells in normal mammary epithelium
We define a stem cell as an undifferentiated cell for which the
mitotic progeny have the potential to generate differentiated
cells throughout the lifespan. Implicit in this definition is that
stem cells have the capacity for self-renewal. A multipotent
stem cell or progenitor gives rise to more than one
differentiated cell type; a pluripotent stem cell forms all of the
differentiated cell types present in a particular tissue.
Although pluripotency is not formally required for the
definition of a stem cell, studies of the haematopoietic system
and other stem cell compartments have revealed that the
most primitive stem cells have the greatest developmental
potential.
The mature lactating mammary gland comprises mesen-
chymal and epithelial elements. The epithelial cells form a
branching network of ducts terminating in lobules, which are
in turn composed of alveoli. The inner luminal epithelial cells
of the ducts and lobules are ensheathed by a basal layer
consisting predominantly of contractile myoepithelial cells. All
epithelial elements are embedded in a fibrofatty connective
tissue matrix [9]. In the human it is from these epithelial
elements that the vast majority of mammary tumours arise,
and therefore it is with the epithelial lineages that we are
primarily concerned. It is noted, however, that epithelial–
stromal interactions are essential for mammary morpho-
genesis and development [10,11]. Moreover, as discussed in
the following, there is increasing evidence that stromal
alterations are integral to the evolution of breast cancer.
In contrast to most mammalian organs, breast development is
not complete in the neonate, consisting only of a limited
network of ducts. At puberty there is extensive ductal
proliferation and branching; during pregnancy there is
formation of lobuloalveolar units that regress at the
termination of lactation [9]. There is therefore generation of
new ductal, lobular and basal/myoepithelial cells in adult life.
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Although these new cells could in principle be produced by
simple division of differentiated cells, the experimental
evidence supports a hierarchical organisation that parallels
other epithelial stem cell compartments [3,4] — with a small
proportion of multipotent mammary epithelial stem cells that
give rise to progressively more committed progenitors, and
ultimately to all three mammary epithelial cell types.
Murine mammary epithelial stem cells
The first evidence in support of a pluripotent mammary
epithelial stem cell can be found in the classic transplantation
experiments of DeOme and colleagues [12]. It was shown in
the mouse that transplantation of small fragments from any
portion of the mammary epithelial tree to a cleared mammary
fat pad regenerates an entire branching mammary epithelial
tree. Furthermore, a fragment can be taken from this
regenerated gland and be serially transplanted to another
cleared mammary fat pad [13]. Formal proof for the existence
of a pluripotent stem cell as opposed to multiple develop-
mentally committed progenitors was not available, however,
until a similar experiment was performed with retrovirally
tagged cells. Neonatal mice were infected with mouse
mammary tumour virus (MMTV), a retrovirus, and randomly
chosen fragments of the gland were transplanted from
multiparous adult animals to the cleared mammary fat pad of
noninfected recipients. Since MMTV integrates at random
into the nuclear genome, clones derived from individual
infected mammary epithelial cells could be distinguished. It
was seen that an entire mammary epithelial tree could be
derived from the progeny of a single MMTV-infected cell [14].
Limiting dilution transplantation experiments also support the
existence of pluripotent epithelial stem cells in the mouse
mammary gland. In these experiments small numbers of
dissociated mammary epithelial cells are transplanted so that
only a minority of fat pads have epithelial outgrowths, with
most of these outgrowths derived from a single mammary
epithelial cell. Three types of outgrowths can be
distinguished. The first generates a limited network of ducts
without lobules, and another type produces a limited out-
growth of lobules without branching ducts. The final outgrowth
type has both ductal and lobular development and completely
fills the mammary fat pad [15,16]. Retroviral labelling
confirms that each of these outgrowths is clonal [14].
Cell surface markers
The dramatic progress made in understanding the haemato-
poietic system in recent years has come about largely as a
consequence of the ability to prospectively identify
haematopoietic stem cells on the basis of cell surface
antigens [17] and as a consequence of the existence of a
robust and well-characterised repopulation assay in the form
of bone marrow transplantation. An analogous repopulation
assay in combination with limiting dilution transplantation has
recently been employed to characterise cells ‘mammary
repopulating units’ (MRUs) within dissociated murine
mammary epithelium that can repopulate a cleared mammary
fat pad with all mammary epithelial lineages [18,19].
Following removal of cells of nonepithelial lineages, MRUs
could be prospectively purified from mammary epithelial cells
on the basis of expression of either CD24+CD29hi [19] or
CD24medCD49fhi [18]. For both of these cell populations a
single cell could give rise to epithelial outgrowths in cleared
mammary fat pads that contained all mammary epithelial
lineages, thereby demonstrating pluripotency. Serial trans-
plantation of cells harvested from these clonal outgrowths to
secondary recipients proved the ability of these cells to self-
renew. Sleeman and colleagues independently found MRUs
to be enriched in the CD24lo population as opposed to
CD24hi and CD24– populations [20]. These studies repre-
sent not only the first reports of prospective identification of
mammary epithelial stem cells, but indeed of any mammalian
epithelial stem cells.
It is necessary to reinterpret preceding studies in the light of
these new results. It has been previously reported that all
cells with the capacity to repopulate the cleared mammary fat
pad express sca-1, a haematopoietic stem cell marker [21].
This finding is not supported by the studies of Shackleton,
Stingl and colleagues; specifically, CD24+CD29hi cells are
not enriched in sca-1+-expressing cells [19] and no MRUs
were detected in the sca-1hi subset of CD29f+ cells [18].
This discrepancy may be accounted for by the observation of
Stingl and colleagues that in-vitro culture per se is sufficient
to induce sca-1 in cultured cells. A further significant finding
of Stingl and colleagues’ study is that mammary epithelial
cells that formed colonies in vitro (mammary colony-forming
cells) expressed an entirely distinct set of cell surface
antigens compared with MRUs. They were also many times
more numerous and could be derived from MRUs, implying
that mammary colony-forming cells are a separate population
of committed progenitors. This has important implications for
studies seeking to define a phenotype for human mammary
epithelial stem cells on the basis of in-vitro culture [22-24].
Characterisation of prospectively purified MRUs offers
insights into their phenotype. Differential staining of mammary
epithelial cells for CD24 separates the different mammary cell
populations with a high degree of purity. Cytokeratin
expression and quantitative PCR reveal that CD24–, CD24lo
and CD24hi populations correspond to nonepithelial cells,
basal/myoepithelial cells and luminal epithelial cells,
respectively [20]. In limited dilution transplantation to the
cleared mammary fat pad, CD24lo cells had the highest
concentration of MRUs and the greatest outgrowth potential.
In contrast, CD24hi cells had a much lower content of MRUs
and were unable to repopulate the entire fat pad, suggesting
that mammary epithelial stem cells have the basal/
myoepithelial phenotype [20]. Consistent with this
interpretation, flow cytometry reveals that a large proportion
of stem cell candidates with the CD24+CD29hi phenotypePage 3 of 11
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express the basal marker cytokeratin 14 [19]. Oligonucleo-
tide array studies and quantitative PCR similarly found higher
levels of cytokeratin 14 and other basal/myoepithelial markers
in the CD24medCD49fhi population. Further examination of the
CD24medCD49fhi population at the single cell level, however,
revealed that while a proportion of cells expressed basal/
myoepithelial-specific markers and others expressed luminal-
specific markers, these were never coexpressed at the single
cell level; moreover, approximately one-half of these cells did
not express markers of either lineage [18].
In the interpretation of these seemingly contradictory findings
it is essential to remember that the frequency of MRUs in the
CD24+CD29hi and CD24medCD49fhi populations is estimated
at 1/64 and 1/60, respectively. Even allowing for loss of
MRUs during the purification and transplantation steps,
therefore, a large majority of the cells within these popula-
tions are transit amplifying cells rather than stem cells.
Furthermore, although the prospectively isolated CD24lo,
CD24+CD29hi and CD24medCD49fhi populations overlap, in
that they contain MRUs, it is unlikely that the identity of the
(majority) nonstem cells in these populations corresponds
exactly. Until more highly purified and better characterised
populations are available, therefore, we must employ great
caution when inferring the properties of mammary epithelial
stem cells from prospectively isolated populations.
Flow cytometric comparison of the DNA and RNA content in
CD24medCD49fhi stem cell candidates reveals that the vast
majority of these cells are actively cycling. Despite the earlier
caveat that only a small proportion of these cells are actually
stem cells, this would not be an unexpected finding since
double-labelling experiments (see later) have shown that a
large proportion of intestinal epithelial label-retaining cells
(LRC) [25] and mammary epithelial LRC [26], which are
believed to correspond to stem cells, are actively cycling.
Moreover, the c-kitbrightThy 1.1loSca-1.1+Lineage– subset of
murine bone marrow cells, which is highly enriched in haemato-
poietic stem cells, regularly traverses the cell cycle [27].
Label-retaining cells
Within stem cell compartments a small fraction of cells retain
the nucleotide label for a large proportion of the lifespan
[28,29], and these LRC are widely believed to be stem cells.
Retention of the label could simply reflect exceedingly slow
turnover; however, recent ‘double-labelling’ experiments with
intestinal epithelium [25] and mammary epithelium [26], in
which long-term LRC are pulsed with a second nucleotide
label, support Cairns’ hypothesis [30] of asymmetrical DNA
strand segregation with persistence of an ‘immortal strand’ in
the stem cell and segregation of newly synthesised DNA to
daughter cells.
LRC can be identified in the murine mammary gland following
labelling during the period of ductal morphogenesis in the
neonate [21,31,32]. Consistent with their proposed identity
as mammary epithelial stem cells, LRC were enriched in the
CD24+CD29hi population [19]. Only a small proportion of
LRC express keratin 14 or keratin 18, markers of epithelial
differentiation [21]. LRC have also been identified in histo-
logically normal human breast tissue implanted in immuno-
deficient mice [33]; however, in that study the interval
between labelling and biopsy was only 2 weeks, so it is
unlikely that these cells are highly enriched in mammary
epithelial stem cells.
Side population
The ability to exclude fluorescent dyes such as Hoescht
33342 from the cytoplasm has been employed to isolate a
‘side population’ (SP) of haematopoietic cells that is highly
enriched in haematopoietic stem cells [34]. An analogous
population has been identified in primary cultured murine
mammary epithelial cells [21] and in uncultured human
mammary epithelial cells [24,33,35] and murine mammary
epithelial cells [35]. Fluorescent dye exclusion results from
the expression of ATP-binding cassette (ABC) family
transporter proteins. In cultured human mammary epithelial
cells, Abcg2 is thought to be responsible for the SP [24];
studies with triple knockout mice have also implicated
Abc1a/1b (Mdr1a/1b) [36]. Unfortunately Abcg2 is
universally expressed at high levels in the luminal epithelium
of lactating murine and human mammary glands [37],
although this does not, in principle, preclude its use as a stem
cell marker in the virgin mammary gland.
It has been proposed that the SP is enriched in mammary
epithelial stem cells. In support of this hypothesis, murine SP
cells give rise to all three mammary epithelial cell lineages
when transplanted to cleared mammary fat pads [21,35];
moreover, human SP cells form much larger branching
colonies in matrigel than do non-SP cells [33]. SP cells are
also highly enriched for mammosphere formation [38]. On the
other hand, possibly as a consequence of Hoescht dye
toxicity, it has never been demonstrated that the SP is
enriched in cells with the capacity to repopulate the cleared
mammary epithelial fat pad, and only a small proportion (less
than 10%) of cells with the capacity to repopulate the cleared
mammary fat pad are contained within the SP [18]. LRC also
constitute only a small proportion of SP cells [21], and so the
jury remains out regarding the precise relationship of SP cells
to mammary epithelial stem cells.
Other stem cell markers
A variety of other markers for mammary epithelial stem cells
have been proposed, including p21CIP1, a cyclin-dependent
kinase inhibitor, and Msi1, a homologue of the Drosophila
Mushashi protein [33]. Since these are not cell surface
antigens, however, they cannot be validated in mammary fat
pad repopulation assays. A further strategy is Cre recom-
binase-induced LacZ expression under control of the whey
acidic protein promotor [39,40]. Mammary epithelial cells
activate the whey acidic protein promotor during pregnancy,
Available online http://breast-cancer-research.com/content/8/3/211leading to recombination at LoxP sites that results in
expression of an intact LacZ transgene in these cells and
their mitotic descendents. Following transplantation to a
cleared mammary fat pad these ‘parity-induced mammary
epithelial cells’ are pluripotent, giving rise to all three
mammary epithelial cell types in addition to duct-limited and
lobule-limited outgrowths, although the presence of additional
LacZ– cells is required for the formation of intact ductal–
lobular structures. Serial transplantation proved the capacity
for self-renewal.
Human mammary epithelial stem cells
It intuitively seems probable that the human mammary
epithelium will be organised along similar lines to that of the
mouse, and recent reports support this premise. Clonal
patches of X-inactivation [41] and loss of heterozygosity [42]
affect large, contiguous regions of breast epithelium, and this
has been interpreted as reflecting origin from a common
pluripotent stem cell — although the alternative possibility that
these alterations arise during development [43,44] cannot be
formally excluded. In-vitro  culture of dissociated human
mammary epithelial cells yields a bipotent myoepithelial/
luminal progenitor and progenitors restricted to basal/myo-
epithelial and luminal lineages. These different progenitors
can be prospectively purified according to expression of a
range of cell surface antigens, including MUC-1, the common
acute lymphoblastic leukaemia antigen, epithelial cell
adhesion molecule and α6-integrin [22-24]. In-vitro culture
failed to identify a pluripotent progenitor capable of forming
ductal cells in addition to luminal cells and basal/
myoepithelial cells. Furthermore, recent reports indicate that
the population of murine mammary epithelial cells initiating
colony formation in vitro is distinct from the population that
repopulates the cleared mammary fat pad [18]. This strongly
suggests that these in-vitro studies are characterising
committed progenitors rather than pluripotent stem cells.
Mammospheres
A human papillomavirus E6/E7-immortalised human mammary
epithelial cell line has been reported that can form all three
mammary epithelial lineages in vitro, although normal function
of these cells was not proven [45]. Inspired by techniques
developed for the culture of neural stem cells [46], single cell
suspensions of human mammary epithelial cells were more
recently cultured at limiting dilution in conditions that prevent
adherence to the substratum [38]. This technique appears to
limit culture-induced differentiation. Under these conditions
most of the cells die by apoptosis, but a small proportion
survives as floating spherical colony ‘mammospheres’. To
assess their developmental potential, these mammospheres
were dissociated into single cells that were cultured at
limiting dilution.
Similar to previous studies unipotent and bipotent
progenitors were isolated, but also a subset of progenitors
that formed all three mammary epithelial cell types was seen.
In addition, a small proportion of mammosphere-derived cells
(~2–4/1000) formed intact ductal–alveolar structures in
three-dimensional matrigel culture. Self-renewal was
demonstrated by dissociation of mammospheres, reculture
and then reaggregation; cells from the secondary
mammospheres and beyond were almost exclusive bipotent
or tripotent [38]. It is unclear why the ability to form
mammospheres should select for primitive progenitors and
stem cells.
Steroid receptor expression
The extent of lifetime oestrogen exposure is a major risk
factor for the development of breast cancer; moreover,
approximately two-thirds of human breast cancers express
the oestrogen receptor, and the oestrogen receptor status of
a patient is highly predictive of response to antioestrogen
therapy [47]. It is therefore important to define the
relationship between mammary epithelial stem cells and
oestrogen receptor expression.
In the human mammary epithelium, 10–20% of cells are
oestrogen receptor-positive. The progesterone receptor is
almost invariably co-expressed and these cells are said to be
steroid receptor-positive. These cells are located exclusively
within the luminal epithelium [48,49], between basal
myoepithelial cells and apical luminal cells [33]. Interestingly,
a population of undifferentiated small light cells that are
candidates for murine epithelial stem cells has previously
been described in this position [16,50]. Steroid receptor-
positive cells were never dividing, although they were often
located adjacent to a dividing cell [48,49], suggesting that
they occupy a relatively high position in the differentiation
hierarchy.
In an attempt to further define the relationship between
steroid receptor expression and mammary epithelial stem
cells, steroid receptor expression was investigated in murine
mammary epithelial LRC. Although a significant proportion of
LRC expressed steroid receptors soon after administration of
the label, at later time periods, when LRC are more highly
enriched in stem cells, only a very small proportion expressed
steroid receptors [21,26]. These results suggest that most
steroid receptor-positive cells are not mammary epithelial
stem cells, but instead are slowly cycling transit amplifying
cells near the top of the differentiation hierarchy.
Clarke and colleagues also looked at steroid receptor
expression in human mammary epithelial cells transplanted to
immunodeficient mice [33]. Fourteen per cent of LRC and a
large proportion of cells expressing other candidate stem cell
markers were found to be steroid receptor-positive. The
chase period was only 2 weeks in this study, however, so it is
unlikely that the LRC are highly enriched in mammary
epithelial stem cells. Furthermore, the markers investigated
(Msi1, p21CIP1, cytokeratin 19) have never been validated in
repopulation assays.
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mammary epithelial lineages are ultimately derived from a
pluripotent self-renewing mammary epithelial stem cell that
gives rise to bilineage-restricted and lineage-restricted
progenitors with limited proliferative potential.
Breast cancer stem cells
With analogy to the previous definition of tissue stem cells
we can define cancer stem cells as cells that can give rise to
all cell types within the tumour and that have the capacity for
self-renewal. Since it has not been proven that cancer stem
cells are derived directly from tissue stem cells, this is not a
requirement of our definition. It has been recognised for some
time that only a small minority of the cells within haemato-
poietic malignancies have the capacity for extensive prolifera-
tion, but the possibility that all tumour cells are equivalent and
that extensive proliferation is merely a stochastic pheno-
menon could not be excluded [6]. In 1997, however, Bonnet
and Dick showed that the subset of acute myeloid leukaemia
(AML) cells capable of transferring the tumour to immuno-
deficient mice can be prospectively identified according to
expression of certain cell surface markers [51]. This proved
that heterogeneity is intrinsic to tumour cells, and provided
strong support for the cancer stem cell hypothesis. Similar
results have since been reported for other haematopoietic
malignancies [5] and neural malignancies [8].
As already described, a number of powerful experimental
methodologies have been developed to characterise epithelial
stem cells. These include the expression of cell surface or
intracellular markers, mammosphere formation, exclusion of
fluorescent dye by a SP and the retention of the radio-
nucleotide label. It is reasonable to suppose that breast cancer
stem cells will share some of the characteristics of normal
mammary epithelial stem cells and, with the exception of label
retention, all of these approaches have also been employed in
efforts to identify breast cancer stem cells within tumours.
Cell surface markers
The gold standard for proving the existence of a
subpopulation of tumourigenic stem cells is the demon-
stration that a minority of prospectively identified cells is able
to transfer the tumour and recapitulate the phenotypic
heterogeneity present within the parental tumour, whereas a
much larger number of tumour cells lacking the relevant
marker(s) cannot. This same subpopulation should again fulfil
these criteria when re-isolated from a secondary tumour. This
is feasible for haematopoietic malignancies since haemato-
poietic cells survive well in suspension and therefore tolerate
the process of sorting and bone marrow transplantation well.
Unfortunately for solid tumours in general, and for breast
cancer in particular, the efficiency of tumour initiation in
immunodeficient mice from primary dissociated tumour cells
is very low. This most probably reflects anoikis in the absence
of binding to a substratum in combination with the trauma of
dissociation and cell sorting.
Two strategies have been successfully employed to
circumvent these limitations and to identify tumourigenic cells
within  breast cancers. Al-Hajj and colleagues initiated
tumours in immunodeficient mice with cells derived from
eight human breast-cancer-associated malignant pleural
effusions [7]. These cells have already survived selection in
vivo for the ability to survive in suspension and to tolerate
low oxygen tensions, and this may account for their tolerance
to cell sorting. Although one tumour was established directly
from a primary breast cancer, cell sorting was only
performed following passage in an immunodeficient mouse.
It was found that a small proportion of tumourigenic cells
could be isolated from dissociated tumour cells by flow
cytometry. Following removal of nonepithelial cells, cells with
the CD44+CD24–/loLin– phenotype were 10-fold to 50-fold
enriched in their ability to initiate tumours compared with
unsorted cells. For three of the malignant pleural effusions,
further enrichment was possible according to expression of
the ESA (epithelial cell adhesion molecule) antigen. As few as
200 CD44+CD24-/loESA+Lin– cells consistently initiated
tumours, whereas 10,000 unsorted cells did so only rarely.
CD44+CD24–/loLin– cells isolated from tumours that had
been initiated by these cells were able to transfer the tumour
to secondary and subsequent hosts, demonstrating the
capacity for self-renewal.
The formation of mammospheres from normal mammary
epithelial cells has already been described. Ponti and
colleagues employed a similar approach to derive
mammospheres from human breast cancers [52].
Mammosphere cells were undifferentiated but, interestingly, a
large majority had the same CD44+CD24– phenotype
reported by Al-Hajj and colleagues. When transferred to
differentiating culture conditions, mammospheres produced
cells of both luminal and basal/myoepithelial lineages.
Mammospheres initiated tumours in the cleared mammary fat
pad of immunodeficient mice at 1000-fold greater dilutions
than established breast-cancer-derived cell lines. Following
enzymatic dissociation, 10–20% of cells from primary
tumour-derived mammospheres formed secondary mammo-
spheres and several cultures were serially expanded for more
than 40 passages, proving a capacity for long-term self-
renewal. Mammospheres from more aggressive tumours
formed a larger number of secondary mammospheres,
suggesting a greater capacity for self-renewal.
Do CD44+/CD24– cells represent breast cancer stem cells?
The results of both Al-Hajj and colleagues and Ponti and
colleagues suggest that breast cancer cells with the
capability for long-term self-renewal are enriched within the
CD44+CD24– subset. We should not, however, infer from
this that the CD44+CD24– subset of tumour cells is a
homogeneous population of cancer stem cells; instead,
analogous to prospectively purified mammary epithelial stem
cells, this population most probably represents a hetero-
geneous mix of cancer stem cells and early progenitor cells.
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Hajj and colleagues’ malignant pleural effusions, an ESA+
subpopulation of CD44+CD24– cells is more highly enriched
in tumourigenic cells [7]. Additionally, although virtually all of
the cells in Ponti and colleagues’ mammospheres were
CD44+CD24–, only 10–20% had the capacity for self-
renewal.
Both of these earlier studies, by necessity, impose an
intervening selection step between primary cancer cells and
cell sorting — the ability to survive in a pleural effusion in the
case of Al-Hajj and colleagues’ experiments, and the ability to
survive in nonadherent culture conditions for Ponti and
colleagues’ study. It therefore remains formally possible that
only the subset of breast cancer stem cells that fulfil these
criteria is identified in these studies.
Side population
A Hoescht dye-effluxing SP has been identified in AML
patients that is highly enriched in the ability to transfer the
disease to immunodeficient mice [53]. This cell population is
believed to contain a high proportion of leukaemia stem cells.
A similar SP has been identified in primary neuroblastoma
cells and cultured cell lines [54] and in certain established
breast-cancer-derived cell lines [54,55]. For a variety of
cultured cell lines it was shown that the SP was enriched in
cells with the ability to initiate tumours in immunodeficient
mice [55], although these studies are somewhat confounded
by the higher concentration of (toxic) Hoescht dye present in
non-SP cells. Future experimental strategies may include the
characterisation of SP cells from primary breast cancers
and/or breast-cancer-derived mammospheres.
Does breast cancer arise from stem cells or from transit
amplifying cells?
For most mammalian malignancies, in particular epithelial
malignancies, genetic alterations accumulate sequentially
[56] until a set sufficient to induce malignant transformation
coexists within a single cell [57,58]. Stem cell compartments
are organised in a hierarchical manner with a small number of
infrequently proliferating pluripotent stem cells, of rapidly
dividing developmentally committed transit amplifying cells
and of post-mitotic terminally differentiated cells [1]. Under
normal circumstances any mutation that occurs in a transit
amplifying cell is lost from the tissue since these cells do not
have the capacity for indefinite self-renewal. It is therefore
likely that the majority of mutations responsible for malignancy
will arise in tissue stem cells [30] or in their developmental
precursors [44]. If a transit amplifying cell sustains a mutation
that confers indefinite self-renewal, however, and in particular
if this cell already has additional mutations required for
malignancy by virtue of descent from a tissue stem cell that
contains these mutations, then malignancy can arise from a
transit amplifying cell. In fact, since transit amplifying cells are
both greater in number and proliferate more frequently than
stem cells, this may be a common route to malignancy.
Most myeloid leukaemias are thought to arise directly from
haematopoietic stem cells. There is evidence, however, that
the M3 acute promyelocytic subtype arises from a transit
amplifying cell that has acquired the capacity for self-renewal
as a consequence of expression of the PML/RARα fusion
protein [5]. When transduced with a leukaemogenic MLL
fusion gene in vitro both haematopoietic stem cells and
committed myeloid progenitors promptly immortalise, and trans-
plantation leads to AML with apparently identical phenotypes
in vivo [59]. This demonstrates not only that malignancy can
arise from transit amplifying cells, but also that cancer stem
cells do not necessarily correspond to tissue stem cells.
Similar studies with mammary epithelium would be most
informative, but unfortunately promotors selectively expressed
in stem cells and committed progenitors have yet to be
identified; in lieu of these, most investigators have employed
the MMTV promotor, which is expressed in a diverse array of
cell types. Nevertheless, there is preliminary evidence that
different oncogenes target different levels of the
differentiation hierarchy. Tumours induced by expression of
Wnt (and downstream members of this pathway) express
markers of both luminal and basal/myoepithelial lineages [60].
This is not seen with other oncogenes such as Neu and
H-Ras, and suggests origin from a pluripotent precursor,
presumably a mammary epithelial stem cell. In support of this
hypothesis the number of CD24+CD29hi stem cell
candidates was increased in MMTV-wnt-1 transgenic mice
but not in MMTV-neu mice [19]. The observation that tumours
initiated by carcinogen treatment of rats contain both luminal
and basal/myoepithelial cells [61] is also consistent with a
stem cell origin for these tumours.
There is an additional route via which mutations arising in
transit amplifying cells can persist within the tissue and
ultimately lead to malignancy. If dedifferentiation of transit
amplifying cells to stem cells is a relatively frequent event,
then mutations that occur in transit amplifying cells can be
‘fixed’. In fact this mechanism may have particular relevance
to mammary carcinogenesis since a population of persistent
mammary epithelial cells has been identified that derive from
differentiated cells produced during pregnancy, that survive
the widespread apoptosis concurrent with post-lactational
involution, that have the capacity for self-renewal on serial
transplantation and that can differentiate to alveolar cells in
subsequent pregnancies (see above) [39,40]. These parity-
induced mammary epithelial cells are the cell of origin for a
substantial proportion of tumours in transgenic mice
expressing the unactivated Her2/neu (ErbB2) oncogene
under the MMTV promotor [62], although this is not seen with
the wnt1 oncogene.
Interactions between malignant epithelial cells and the
stroma
Although we have focused on genetic alterations in breast
epithelial elements, there is increasing evidence that stromal
Breast Cancer Research    Vol 8 No 3 Lynch et al.
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[63,64]. The breast stroma accounts for 80% of the breast
volume and comprises fibroblasts, adipocytes and endothelial
cells. It has been demonstrated that tumour-associated
stromal cells promote the development of epithelial malig-
nancy in vitro and in vivo: premalignant mammary epithelial
cells adopt a malignant growth pattern when cultured with
tumour-derived stromal cells [65] or when transplanted to
transplanted to irradiated mammary fat pads [66], but not
when cultured in the presence of normal mammary stromal
cells or transplanted to nonirradiated fat pads. Administration
of the carcinogen NMU to mammary fat pad stromal cells is
sufficient to induce tumour formation following repopulation
with normal mammary epithelial cells [67].
The persistence of tumour promotion by breast cancer-
associated stromal cells following passage in culture [65]
suggests hereditable changes, and clonal genetic alterations
[68-71] and epigenetic alterations [72] have been described.
For an individual tumour the alterations observed in stromal
cells differ from those in malignant epithelial cells, arguing
against epithelial–mesenchymal transition. A genome-wide
loss of the heterozygosity scan in stromal cells from a number
of breast tumours revealed hotspots that were more
frequently mutated [71]. This indicates that selective
pressures operate during the expansion of tumour-associated
stromal cells and that alterations do not merely reflect genetic
drift. The precise mechanisms mediating tumour promotion
remain unclear; candidates include alterations in expression
of growth factors and matrix remodelling enzymes, the
recruitment of inflammatory cells and the elaboration of viral
oncoproteins [63].
Implications for therapy
Techniques that permit accurate quantification of the
proportion of cancer stem cells in a tumour will permit
assessment of the efficacy of current treatment modalities
and will guide clinical decision-making. Further character-
isation of breast cancer stem cells may enable the design of
targeted therapeutics that selectively destroy these cells and
block their self-renewal.
Quantification of breast cancer stem cells
The efficacy of chemotherapy regimens, particularly in the
neoadjuvant setting, is usually gauged by the proportion of
tumour cells killed. This is reflected clinically by a reduction in
size of the tumour. Since cancer stem cells represent a small
proportion of the cells within breast tumours, a particular
treatment modality could in principle kill a large proportion of
differentiated cells while leaving tumour stem cells intact. In
fact, CD34+CD38– cells isolated from patients with AML are
more resistant to daunorubicin than more differentiated
progenitors [73], suggesting that cancer stem cells may have
relative resistance to chemotherapy regimens. The ability to
accurately quantify the proportion of cancer stem cells within
a tissue sample will permit the identification of treatment
regimens that efficiently eliminate cancer stem cells. It will
also be instructive to determine whether the proportion of
stem versus transit amplifying cells in a given tumour has
implications for prognosis.
A related issue is bone marrow micrometastasis. Cytokeratin-
expressing cells can be detected in the bone marrow of
around one-third of patients with breast cancer and are an
independent predictor of poor outcome [74,75]. Importantly
these cells are also found in lymph-node-negative patients,
and it has been proposed that this may account for the
relatively high rate of systemic recurrence in this group of
patients. Conversely, a substantial proportion of patients with
bone marrow micrometastasis do not develop tumour
recurrence. Cytokeratin-positive cells within the bone marrow
may comprise both cancer stem cells and committed
progenitors with limited proliferative potential. This may have
prognostic significance with patients that have a larger
proportion of breast cancer stem cells more likely to suffer
recurrence. The ability to distinguish cancer stem cells from
other tumour cells within the bone marrow may also have
implications for the selection of adjuvant therapies.
Targeting of breast cancer stem cells
With the emergence of the cancer stem cell paradigm has
come the realisation that, since only a small proportion of
tumour cells have the capacity to self-renew and propagate
the tumour, it is this small proportion of tumour cells rather
than transit amplifying cells or differentiated cells that must be
targeted to achieve long-term cure.
Chemotherapy sensitisation
One approach is to sensitise breast cancer stem cells to
existing chemotherapy regimens. Multidrug resistance has for
many years been recognised as a hindrance to effective
chemotherapy. This is the phenomenon whereby exposure of
cancer cells to a cytotoxic compound leads to resistance not
only to that compound, but also to a range of structurally
unrelated compounds. A wide variety of pathways have been
implicated, including decreased topoisomerase II expression,
reduced sensitivity to apoptosis via alterations in the
expression of Bcl2 family members and the efflux of
chemotherapeutic agents from cancer cells [76]. Several of
these mechanisms, in particular resistance to DNA damage
and the efflux of toxic compounds, are also advantageous in
tissue stem cells, and their activation in malignancy may
reflect not only somatic mutation, but also their intrinsic
activation in the tissue stem cells from which cancer arises.
Moreover, since cancer stem cells are at the top of the
differentiation hierarchy, they will cycle less frequently than
other tumour cells and therefore have a greater resistance to
antimitotics.
Attention has focused on upregulation of cell surface
transporters of the ABC family, in particular ABCG2. This
was initially identified as a transcript overexpressed in
Available online http://breast-cancer-research.com/content/8/3/211
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breast cancer resistance protein [77]. It has since been
implicated in the efflux of Hoescht dye from a SP of stem cell
candidates isolated from mammary epithelial stem cells (see
earlier). The finding of ABCG2 expression in relapsed
haematological malignancies has stimulated the development
of specific inhibitors [78]. Promising inhibitors for another
ABC family transporter implicated in multidrug resistance,
P-glycoprotein, are also entering clinical trials [79]. In order to
achieve long-term remission, cancer stem cells rather than
transit amplifying cells must be destroyed; however, there is
evidence that cancer stem cells have a greater resistance to
chemotherapeutic agents [73]. The co-administration of
inhibitors of the ABC family of transporters and other
inhibitors of multidrug resistance may selectively sensitise
breast cancer stem cells to chemotherapy.
Signalling pathways implicated in the self-renewal of breast
cancer stem cells will provide novel therapeutic targets, and
this has stimulated attempts to characterise these pathways.
Wnt
The Wnt signalling pathway is implicated in the regulation of
the stem cell number in a number of tissues, and
overexpression leads to a range of malignancies [80]. Wnt is
a secreted protein with an intracellular effector, β-catenin
[81]. Loss of Wnt inhibitors (such as SFRP1) and increased
levels of β-catenin have been associated with poor prognosis
in breast cancer [82,83]. β-Catenin has been identified as a
crucial survival signal for mammary epithelial stem cells [84].
Mammary tumours arising in mice overexpressing compo-
nents of this pathway contain cells of both basal/
myoepithelial and luminal phenotypes, suggesting an origin
from a common precursor [60]. Mammary epithelial cells
derived from mice expressing ∆Nβcat, a constitutively active
β-catenin mutant, more efficiently repopulate a cleared
mammary fat pad, suggesting more efficient stem cell self-
renewal [85]. With obvious relevance to potential therapies,
Gunther and colleagues utilised a doxycycline-inducible
wnt-1 transgene to show that withdrawal of wnt signalling is
sufficient to induce regression of primary mammary tumours
and pulmonary metastases [86].
Notch
A second pathway implicated in mammary carcinogenesis is
Notch [87]. Mice expressing a constitutively active form of
Notch4 [88] but not other Notch homologues [89] have
abnormal mammary morphogenesis and develop mammary
tumours. A Notch activating peptide increased secondary
and tertiary mammosphere formation 10-fold and increased
the proportion of cells with multilineage differentiation
capacity 100-fold, implying increased mammary stem cell
self-renewal [38]. Notch signalling was shown to act on stem
cells to promote self-renewal and on progenitors promoting
their proliferation. These effects were completely abrogated
by the use of a Notch4 blocking antibody [90].
Hedgehog
The Hedgehog pathway has been implicated in a range of
malignancies [91,92]. Overexpression of components of this
pathway, including Shh, Ptch1 and Gli1, is found in a large
majority of human breast cancer specimens but not in
adjacent normal epithelium consistent with constitutive
activation of this pathway [93]. In mice, Ptc-1 haplo-
insufficiency leads to abnormal mammary development with
ductal dysplasia and hyperplasia by 5 weeks of age [94]. Gli1
heterozygosity results in abnormal mammary development
with ductal dysplasia in parous animals [95]. These results
must be interpreted with caution, however, as abnormal
mammary development in the Ptc-1 and Gli1 heterozygotes is
abrogated on transplantation to a cleared wild-type fat pad
[94,95], indicating that the phenotype may be expressed in
stromal rather than epithelial cells.
Future prospects
The spectacular success of the tyrosine kinase inhibitor
imatinib in chronic myeloid leukaemia provides a prototype for
targeted therapeutics. While these therapeutics can induce
dramatic tumour regression even in established malignancy,
however, they do not in general lead to a cure but rather
control the disease with recurrence on cessation. They are
also vulnerable to the emergence of resistant clones with
prolonged therapy [96]. This most probably reflects genetic
instability in established malignancy and a large number of
cells that are targets for mutation. These observations raise
fundamental questions about our approach to the control of
malignancy. The emerging paradigm for multistep
carcinogenesis in epithelial malignancy is a long period of
clonal evolution in histologically normal tissue [58], for which
a substantial proportion of genetic alterations may occur
during development [44]. This leads to histological atypia,
dysplasia, pre-invasive disease and, finally, malignancy with
the capacity for invasion and metastasis.
Nonsurgical treatment strategies for breast cancer are at
present reserved for the treatment of established malignancy,
but from first principles any stage in the evolution of
malignancy can be targeted. In fact, therapies targeting
pathways that govern self-renewal of preinvasive disease
such as ductal carcinoma in situ, or even mutant stem cells in
histologically normal tissue, may be more effective since the
mutation rate is lower at this stage, since there is less likely to
be coexistent mutations that confer resistance and since
there is a smaller number of target cells for the emergence of
resistance. Furthermore, metastasis may occur early in the
history of breast cancer — frequently before the tumour
becomes apparent clinically or on screening. Since it is
probable that a large proportion of otherwise healthy women
have cells containing these genetic alterations, this approach
could only succeed if a large proportion of apparently healthy
women are treated — necessitating a paradigm shift in our
approach to breast cancer, and to epithelial malignancy in
general.
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targeting the self-renewal of mammary epithelial stem cells.
Since the mammary epithelium is unimportant cosmetically,
such compounds could be administered to ablate the
mammary epithelium in women carrying hereditary breast
cancer susceptibility genes such as BRCA1/BRCA2. For
women not carrying breast cancer susceptibility genes,
however, such an approach may be unacceptable, and
therefore in the longer term it is desirable to develop methods
permitting repopulation with stem cells derived either from
tissue stem cells expanded in vitro or differentiated from
embryonic stem cells. Transplanted stem cells could be
modified to confer a selective advantage over endogenous
stem cells, as has been reported for haematopoietic stem
cells [97]. Transplanted cells could also be modified to
reduce susceptibility to malignancy; for example, transgenic
mice with extra copies of the p53 [98] and INK4A [99]
tumour suppressor genes have a substantially decreased
incidence of malignancy in the absence of apparent adverse
consequences. Although repopulation of mammary stem cells
remains a rather distant prospect, intraluminal injection of
donor spermatocyte stem cells into seminiferous tubules
repopulates the testes of sterile mice leading to normal
spermatogenesis [100], so there is no reason to suppose
that it should not be technically feasible.
Conclusions
There is substantial evidence that proliferation within the
normal mammary epithelium is organised in a hierarchical
manner. Repopulation experiments and lineage analysis
support the existence of pluripotent mammary epithelial stem
cells, and cell surface markers have been identified to
facilitate their purification. Similar techniques have been
employed to prospectively isolate breast cancer stem cells.
Although a substantial amount of work remains in the further
purification and characterisation of these cells, there is little
doubt that these new discoveries have profound implications
for tailoring of current treatment strategies and for the
development of the next generation of targeted therapies.
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